Company: SUPN
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0001104659-25-042531
Chunk: 60

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 60
---
 ​ | 76,000(5)  | ​ | ​ | ​ | ​                 | ​ |    150,010 | ​ | ​ | ​ | ​                  | ​ | 142,678 | ​ | ​ | ​ | ​        | ​ | 368,688 | ​ | ​ |
| Bethany L. Sensenig          | ​ | ​ | ​                            | ​ | 62,500(6)  | ​ | ​ | ​ | ​                 | ​ |    150,010 | ​ | ​ | ​ | ​                  | ​ | 142,678 | ​ | ​ | ​ | ​        | ​ | 355,188 | ​ | ​ |
| John M. Siebert, Ph.D.       | ​ | ​ | ​                            | ​ | 46,250(7)  | ​ | ​ | ​ | ​                 | ​ | 162,520(7) | ​ | ​ | ​ | ​                  | ​ | 142,678 | ​ | ​ | ​ | ​        | ​ | 351,448 | ​ | ​ |

(1) Amounts represent the grant date fair value of our common stock calculated in accordance with ASC 718. The grant date of each stock and option award was February 22, 2024, except with respect to Ms. Sensenig who was not yet serving on the Board on such date and whose option award has a grant date of August 17, 2023. (2) Dr. Gemayel received a $50,000 annual Board retainer and $12,500 for his service as a member of the Audit Committee, $10,000 for his service as a member of the Compensation Committee, $10,000 for his service as a member of the Science Committee, and $6,000 for his service as a member of the Governance and Nominating Committee. (3) Mr. Hudson received a $50,000 annual Board retainer, $25,000 for service as Chairman of the Audit Committee, and $10,000 for his service as a member of the Compensation Committee.

45

(4) Mr. Newhall received a $50,000 annual Board retainer, a $35,000 retainer for his service as Chairman of the Board, $12,000 for his service as Chairman of the Governance and Nominating Committee, and $10,000 for his service as a member of the Compensation Committee. (5) Dr